Expertise in
15
conditions

Qian M. Jiang

Jiefang Avenue. 1095, 
Wuhan, CN 
Expertise in
15
conditions
Jiefang Avenue. 1095, 
Wuhan, CN 
OverviewLocationsClinical Research

Overview

Qian Jiang practices in Wuhan, China. Mr. Jiang is highly rated in 15 conditions, according to our data. His top areas of expertise are Chronic Myelogenous Leukemia (CML), Leukemia, Acute Myeloid Leukemia (AML), Bone Marrow Transplant, and Thrombectomy.

His clinical research consists of co-authoring 549 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Jiefang Avenue. 1095, Wuhan, 430030, China
Other Locations
158 Shangtang Road, Hangzhou, 310014, China
North Branch, Chongqing, 401147, China
438 North Jiefang Street, Zhenjiang, 212001, China
11 Xi Zhi Men South Street, Beijing, 100044, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Enrollment Status: Active_not_recruiting
Publish Date: April 04, 2025
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Single-arm, Open-label, Dose Escalation and Dose Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Patients With Refractory or Advanced CML
A Single-arm, Open-label, Dose Escalation and Dose Expansion Phase 1 Trial to Determine the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Patients With Refractory or Advanced CML
Enrollment Status: Active_not_recruiting
Publish Date: February 24, 2025
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

549 Total Publications

Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation
Incidence and associated factors of tyrosine kinase inhibitor withdrawal syndrome and psychological issues in patients with chronic-phase chronic myeloid leukemia after therapy discontinuation
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Jiang's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 81 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile